COVID-19患者的凝血病、静脉血栓栓塞与抗凝治疗
本文综述COVID-19相关凝血病的病理生理、静脉血栓栓塞(VTE)风险及抗凝防治。观察性研究显示普通病房和ICU患者VTE发生率意外偏高,即使已接受标准或更高强度药物预防。缺乏高质量随机对照试验,各国际指南共识不全一致,作者整合文献形成临床考虑要点。
要点
- COVID-19可致炎症、高凝、低纤溶状态的凝血病,VTE风险在普通病房和ICU均高。
- 标准或更高强度药物预防下,观察性研究仍报告高VTE发生率。
- 高质量RCT缺乏,国际指南共识不全一致,需综合文献制定临床决策。
核心结论
- COVID-19患者存在明显血栓潜能,凝血病表现为炎症、高凝和低纤溶状态。
- 观察性研究显示普通病房和ICU患者VTE发生率高,即使接受标准或更高强度药物预防。
- 缺乏高质量随机对照试验,国际指南共识不全一致,作者整合文献形成临床考虑要点。
研究设计与样本
- 本文为文献综述,通过文献检索汇总COVID-19凝血病、VTE风险及抗凝防治的最新信息。
- 综述涵盖病理生理、凝血病、VTE风险、预防与治疗,以及抗凝药选择与疗程等实践问题。
主要发现
- 观察性研究显示普通病房和ICU的COVID-19患者VTE发生率意外偏高。
- 许多观察性研究中,患者接受标准或更高强度药物VTE预防仍出现高VTE发生率。
- 纤溶治疗已用于急性呼吸窘迫综合征患者。
- 高质量随机对照试验缺乏。
临床怎么用
- 临床医生可参考作者整合文献形成的临床考虑要点,用于COVID-19患者VTE预防和治疗。
- 抗凝决策需考虑抗凝药选择与疗程等实践问题。
局限性
- 缺乏高质量随机对照试验。
- 各国际组织指南或共识声明未覆盖相同抗凝治疗问题,且不全一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a worldwide pandemic, and patients with the infection are referred to as having COVID-19. Although COVID-19 is commonly considered a respiratory disease, there is clearly a thrombotic potential that was not expected. The pathophysiology of the disease and subsequent coagulopathy produce an inflammatory, hypercoagulable, and hypofibrinolytic state. Several observational studies have demonstrated surprisingly high rates of venous thromboembolism (VTE) in both general ward and intensive care patients with COVID-19. Many of these observational studies demonstrate high rates of VTE despite patients being on standard, or even higher intensity, pharmacologic VTE prophylaxis. Fibrinolytic therapy has also been used in patients with acute respiratory distress syndrome. Unfortunately, high quality randomized controlled trials are lacking. A literature search was performed to provide the most up-to-date information on the pathophysiology, coagulopathy, risk of VTE, and prevention and treatment of VTE in patients with COVID-19. These topics are reviewed in detail, along with practical issues of anticoagulant selection and duration. Although many international organizations have produced guidelines or consensus statements, they do not all cover the same issues regarding anticoagulant therapy for patients with COVID-19, and they do not all agree. These statements and the most recent literature are combined into a list of clinical considerations that clinicians can use for the prevention and treatment of VTE in patients with COVID-19.
引用
- Dobesh PP, Trujillo TC. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacotherapy. 2020. PMID: 33006163. doi:10.1002/phar.2465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。